My take is that effectiveness of FTY720 and its 0.5mg dose better safety data, will likely nudge the risk/reward profile towards approval.
NVS' 2nd generation S1P agonist, BAF312, should have a better risk/reward profile as it doesn't acts on all five S1P receptors. It works on S1P1 which is believed to modulate immune response and on S1P5, which is expressed predominantly on neurons and oligodendricytes and appears to play a role in neuron survival. S1P3 is believed to mediate the vascular and bronchial side effects found with FTY720.
Market Data 
Markets 
AI
